- Niraparib maintenance therapy is similarly safe and effective in older patients (age, ≥70 years) vs their younger counterparts with recurrent ovarian cancer, regardless of BRCA status.
Why this matters
- Current guidelines recommend same standard-of-treatment for older and younger patients.
- Randomized, double-blind, phase 3 ENGOT-OV16/NOVA trial.
- Patients with recurrent ovarian, fallopian tube, or peritoneal cancer, with or without a germline BRCA mutation (gBRCA and non-gBRCA cohorts), were randomly assigned 2:1 to maintenance niraparib or placebo.
- Funding: TESARO, Inc.
- Median follow-up in the niraparib group: 17.3 and 17.2 months in patients aged ≥70 and
- In the gBRCA cohort, niraparib prolonged median PFS vs placebo in
- patients aged
- patients aged ≥70 years (not reached vs 3.7 months; HR, 0.09; 95% CI, 0.01-0.73).
- In the non-gBRCA cohort, median PFS was significantly higher with niraparib in patients aged
- Patients aged ≥70 vs
- Post hoc analysis.